SEARCH

SEARCH BY CITATION

References

  • 1
    Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke. 1990;21:637676.
  • 2
    Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack. A scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. Stroke. 2009;40:22762293.
  • 3
    Shah SH, Saver JL, Kidwell CS, et al. A multicenter, pooled, patient-level data analysis of diffusion-weighted MRI in TIA patients. Stroke. 2007;38:463.
  • 4
    Johnston SC, Fayad PB, Gorelick PB, et al. Prevalence and knowledge of transient ischemic attack among US adults. Neurology. 2003;60:14291434.
  • 5
    Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology. 2005;64:817820.
  • 6
    Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284:29012906.
  • 7
    Giles MF, Rothwell PM. Risk of stroke early after transient ischemic attack: a systematic review and meta-analysis. Lancet Neurol. 2007;6:10631072.
  • 8
    Wu CM, McLaughlin K, Lorenzetti DL, et al. Early risk of stroke after transient ischemic attack. A systematic review and meta-analysis. Arch Intern Med. 2007;167:24172422.
  • 9
    Chandratheva A, Meta Z, Geraghty OZ, et al. Population-based study of risk and predictors of stroke in the first few hours after a TIA. Neurology. 2009;72:19411947.
  • 10
    Weimar C, Benemann J, Huber R, et al. Long-term mortality and risk of stroke after transient ischemic attack. J Neurol. 2009;256:639644.
  • 11
    Clark TG, Murphy MFG, Rothwell PM. Long-term risks of stroke, myocardial infarction, and vascular death in “low risk” patients with a non-recent transient ischemic attack. J Neurol Neurosurg Psychiatry. 2003;74:577580.
  • 12
    Bos MJ, van Rijn MJE, Witteman JCM, et al. Incidence and prognosis of transient neurological attacks. JAMA. 2007;298:28772885.
  • 13
    Johnson P, Rosewell M, James MA. How good is the management of vascular risk after stroke, transient ischemic attack or carotid endarterectomy? Cerebrovasc Dis. 2007;23:156161.
  • 14
    Antithrombotic Trialists’ Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:18491860.
  • 15
    Lievre M, Cucherat M. Aspirin in the secondary prevention of cardiovascular disease: an update of the APTC meta-analysis. Fundam Clin Pharmacol. 2010;24(3):385391.
  • 16
    Sandercock PAG, Counsell C, Gubitz GJ, Tseng MC. Antiplatelet therapy for acute ischemic stroke. Cochrane Database Syst Rev. 2008:CD000029. doi: 10.1002/14651858.CD000029.pub2.
  • 17
    Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:227276.
  • 18
    Ridker PM, Cook NR, Lee I, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:12931304.
  • 19
    Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453463.
  • 20
    Aronow HD, Califf RM, Harrington RA, et al. Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO trial). Am J Cardiol. 2008;102:12851290.
  • 21
    Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose with clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009;150:379386.
  • 22
    The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325:12611266.
  • 23
    Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:10441054.
  • 24
    Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ. 2002;324:7186.
  • 25
    Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:113.
  • 26
    The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:16651673.
  • 27
    DeSchryver E, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev. 2007;18:CD001820. doi: 10.1002/14651858.CD001820.pub3.
  • 28
    Bristol-Myers Squibb/Sanofi Pharmaceuticals. Plavix [package insert]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals; 2009.
  • 29
    CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:13291339.
  • 30
    Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patient (MATCH): randomised, double-blind placebo-controlled trial. Lancet. 2004;364:331367.
  • 31
    Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:12381251.
  • 32
    FDA Drug Safety Communication. Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm/203888.htm#ds. Accessed April 1, 2010.
  • 33
    Sandercock PAG, Gibson LM, Liu M. Anticoagulants for preventing recurrence following presumed non-cardioembolicischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2009;15:CD000248. doi: 10.1002/14651858.CD000248.pub2.FDA Drug Safety.
  • 34
    The ESPRIT Study Group. Medium-intensity oral anticoagulants versus aspirin after cerebral ischemia of arterial origin (ESPRIT): a randomized controlled trial. Lancet Neurol. 2007;6:115124.
  • 35
    European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:12551262.
  • 36
    Blackshear JL, Halperin JL, Hart RG, et al. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet. 1996;348:633638.
  • 37
    Saxena R, Kuodstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev. 2004;18:CD000187. doi: 10.1002/14651858.CD000187.pub2.
  • 38
    Serebruany VL, Malinin AI, Ferguson JJ. Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundam Clin Pharmacol. 2008;22:315321.
  • 39
    Usman MHU, Notaro LA, Nagarakanti R, et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol. 2009;103:11071112.
  • 40
    Rothwell PM, Coull AJ, Giles MF, et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 (Oxford Vascular Study). Lancet. 2004;363:925933.